Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Non-Comparative Open Pilot Trial to Assess the Safety and Pharmacokinetics of up to Three Single Doses of AERUMAB 11 (KBPA-101) in Patients With Hospital Acquired Pneumonia Caused by Serotype O11 P. Aeruginosa.

Next Previous
Search
Trial Profile

A Non-Comparative Open Pilot Trial to Assess the Safety and Pharmacokinetics of up to Three Single Doses of AERUMAB 11 (KBPA-101) in Patients With Hospital Acquired Pneumonia Caused by Serotype O11 P. Aeruginosa.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Aug 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Panobacumab (Primary)
  • Indications Nosocomial pneumonia; Pseudomonal infections; Ventilator associated pneumonia
  • Focus Adverse reactions; Pharmacokinetics; Registrational
  • Sponsors Kenta Biotech

    • Most Recent Events

    • 03 Jul 2012 Planned number of patients changed from 15 to 40 as reported by EudraCT.
    • 15 Apr 2010 Results were presented at the 20th European Congress of Clinical Microbiology and Infectious Diseases (Abstract No. 1126), according to a Kenta Biotech media release.
    • 14 Sep 2009 Phase IIa data has been presented in a poster session at the 49th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), according to a Kenta Biotech media release.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top